A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib - Trial NCT06284486
Access comprehensive clinical trial information for NCT06284486 through Pure Global AI's free database. This Phase 2 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
Phase 2
Jul 31, 2024
Dec 30, 2028
Primary Outcome
Safety and adverse events (AEs)
Summary
To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06284486
Non-Device Trial